Company Titan Pharmaceuticals, Inc.

TTNP

US8883147055

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-23 pm EDT			5-day change	1st Jan Change
7.01 ^USD	0.00%		-1.27%	-15.03%

Apr. 01	Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 26	Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	MT

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Number of employees: 4

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	1	100.0 %	0	100.0 %	-66.97%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	1	100.0 %	0	100.0 %	-66.97%

Members of the board	Title	Age	Since
Avraham Ben-Tzvi BRD	Director/Board Member	53	22-08-14
Gim Shen Seow CEO	Chief Executive Officer	42	23-10-11
Brynner Chiam BRD	Director/Board Member	-	23-10-11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	914,234	498,544 ( 54.53 %)	0	54.53 %
Stock B	0	950,000	0	0

Name	Equities	%	Valuation
Choon Hau Choong 32.06 %	241,531	32.06 %	2 M $
Truist Bank 4.149 %	31,255	4.149 %	223 786 $
Renaissance Technologies LLC 0.8982 %	6,766	0.8982 %	48 445 $
David Lazar 0.6637 %	5,000	0.6637 %	35 800 $
Geode Capital Management LLC 0.5837 %	4,397	0.5837 %	31 483 $
Vanguard Group, Inc. (Subfiler) 0.5447 %	4,103	0.5447 %	29 377 $
Katherine Beebe-DeVarney 0.4409 %	3,321	0.4409 %	23 778 $
Matthew McMurdo 0.4398 %	3,313	0.4398 %	23 721 $
Avraham Ben-Tzvi 0.4398 %	3,313	0.4398 %	23 721 $
Eric Greenberg 0.4398 %	3,313	0.4398 %	23 721 $

Name	Equities	%	Valuation
Sire Group Ltd. 100.00 %	950,000	100.00 %	391 400 $

Titan Pharmaceuticals, Inc.

400 Oyster Point Boulevard Suite 505

94080-1958, South San Francisco

+650 244 4990

http://www.titanpharm.com

address Titan Pharmaceuticals, Inc.(TTNP)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
TITAN PHARMACEUTICALS, INC.	-15.03%	6.41M
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals